Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC By Ogkologos - April 30, 2026 78 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... November 28, 2022 Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate... January 11, 2022 Satisfying Snacks November 13, 2020 CEDM Reveals A Clearer Image Of Potential Breast Cancer And Reduces... October 22, 2019 Load more HOT NEWS Rucaparib Extends PFS in the Maintenance Treatment of Recurrent EOC Without... 5-Year-Old Boy Meets Generous Stem Cell Donor Who Cured Him New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations
